首页> 外文OA文献 >Acquired resistance to combination treatment through loss of synergy with MEK and PI3K inhibitors in colorectal cancer

【2h】

Acquired resistance to combination treatment through loss of synergy with MEK and PI3K inhibitors in colorectal cancer

机译：通过与大肠病癌中的MEK和PI3K抑制剂的协同作用丧失获得结合治疗的抵抗力

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Bhaskar Bhattacharya; Sarah Hong Hui Low; Mei Ling Chong; Dilys Chia; King Xin Koh; Nur Sabrina Sapari; Stanley Kaye; Huynh Hung; Touati Benoukraf; Richie Soong;
展开▼
作者单位

展开▼
年度 2016
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Increased EDN1 expression mediates acquired resistance to the combination therapy of PI3K and MEK inhibitors for colorectal cancer [J] . Bhattacharya B., Low S. H. H., Benoukraf T., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2014,第Suppla6期

机译：EDN1表达的增加介导了对PI3K和MEK抑制剂联合治疗结直肠癌的获得性耐药
2. Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated by NRAS or MEK Mutations. [J] . James G Greger, Stephen D Eastman, Vivian Zhang, Molecular cancer therapeutics . 2012,第4期

机译：由NRAS或MEK突变介导的BRAF，MEK和PI3K / mTOR抑制剂的组合克服了对BRAF抑制剂GSK2118436 Dabrafenib的获得性耐药。
3. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells [J] . MartinelliE., TroianiT., DAiutoE., International Journal of Cancer =: Journal International du Cancer . 2013,第9期

机译：pimasertib（一种选择性的MEK 1/2抑制剂）与PI3K / mTOR抑制剂或多靶点激酶抑制剂联合在耐pimasertib的人肺癌和大肠癌细胞中的抗肿瘤活性
4. Network Entropy Reveals that Cancer Resistance to MEK Inhibitors Is Driven by the Resilience of Proliferative Signaling [C] . Joel Maust, Judith Leopold, Andrej Bugrim International Conference on Complex Networks and Their Applications . 2020

机译：网络熵揭示了对MEK抑制剂的抗性抗性由增殖信号传导的抗性驱动
5. Targeting the MEK5, MEK1/2, and/or Pi3k Pathways Reverses Epithelial to Mesenchymal Transition and Enhances Chemotherapeutic Sensitivity in Breast and Brain Cancers with a Mesenchymal Phenotype [D] . Bhatt, Akshita B. 2021

机译：靶向MEK5，MEK1 / 2和/或PI3K途径将上皮细胞转型的上皮性反转，并通过间充质表型提高乳腺癌和脑癌中的化疗敏感性
6. Acquired resistance to combination treatment through loss of synergy with MEK and PI3K inhibitors in colorectal cancer [O] . Bhaskar Bhattacharya, Sarah Hong Hui Low, Mei Ling Chong, 2016

机译：通过与MEK和PI3K抑制剂失去协同作用获得对结直肠癌的联合治疗耐药性
7. Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated by NRAS or MEK Mutations [O] . James G. Greger, Stephen D. Eastman, Vivian Zhang, 2012

机译：BRAF，MEK和PI3K / MTOR抑制剂的组合克服了由NRAS或MEK突变介导的BRAF抑制剂GSK2118436 Dabrafenib的获得性抗性

Acquired resistance to combination treatment through loss of synergy with MEK and PI3K inhibitors in colorectal cancer

著录项

引文网络

相似文献

相关主题

期刊订阅